-

Ollin Biosciences Announces Upcoming Presentations of OLN324 Data in Diabetic Macular Edema and Wet Age-Related Macular Degeneration at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced upcoming oral presentations featuring results from its randomized, head-to-head Phase 1b JADE clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS) 44th Annual Scientific Meeting, taking place from July 15–18 in Montreal, Canada.

OLN324 is a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody entering Phase 3 clinical development for DME and wAMD in the second half of 2026. In the Phase 1b JADE study, OLN324 demonstrated meaningfully faster and greater anatomic outcomes in both DME and wAMD versus faricimab, as well as numerically greater vision gains. Ollin announced final data from the JADE study in March 2026.

Presentation details:

Title: Results of a Randomized, Proof-of-Concept Phase 1b Clinical Trial Comparing OLN324 with Faricimab in Patients with Neovascular Age-Related Macular Degeneration
Presentation Date/Time: Thursday, July 16, 8:15 a.m. – 8:37 a.m. EDT
Presenter: David Eichenbaum, M.D., FASRS, partner and director of research at Retina Vitreous Associates of Florida

Title: Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 With Faricimab in Patients with Diabetic Macular Edema
Presentation Date/Time: Thursday, July 16, 2:04 p.m. – 2:29 p.m. EDT
Presenter: Veeral Sheth, M.D., MBA, FASRS, partner and director of clinical trials, University Retina; clinical assistant professor at the University of Illinois at Chicago

About OLN324

Building on the clinical success of intravitreal VEGF/Ang2 inhibition, OLN324 is a next-generation VEGF/Ang2 bispecific antibody engineered with substantially higher Ang2 potency relative to faricimab, increased molar dosing relative to both faricimab and aflibercept (including Eylea HD®), and a smaller protein format. VEGF and Ang2 are central drivers of retinal vascular diseases such as diabetic macular edema (DME) and wet (neovascular) age-related macular degeneration (wAMD), with Ang2 playing a key role in vascular instability, leakage, inflammation, and fibrosis. In the recently completed head-to-head Phase 1b JADE clinical study comparing OLN324 to faricimab (Vabysmo®), OLN324 demonstrated meaningfully faster and greater anatomic outcomes in both DME and wAMD versus faricimab as well as numerically greater vision gains. Ollin plans to initiate global Phase 3 trials of OLN324 in DME and wAMD in the second half of 2026. OLN324 was discovered by and is being developed in collaboration with Innovent Biologics (HKEX: 01801; Innovent R&D code: IBI324).

About Ollin Biosciences

Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what’s possible in ophthalmology. For more information, please visit us at www.ollin.bio and follow us on LinkedIn and X.

Vabysmo® is a registered trademark of Genentech, Inc.; Eylea® and Eylea HD® are registered trademarks of Regeneron Pharmaceuticals, Inc.

Contacts

Media:
Katie Engleman
1AB
katie@1abmedia.com

Ollin Biosciences, Inc.


Release Versions

Contacts

Media:
Katie Engleman
1AB
katie@1abmedia.com

More News From Ollin Biosciences, Inc.

Ollin Biosciences and Its Next-Generation Medicines for Patients with Vision-Threatening Eye Diseases to be Acquired

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (“Ollin”), a privately-held clinical-stage biopharmaceutical company developing therapies for serious eye diseases, today announced it has entered into a definitive agreement to be acquired by Johnson & Johnson for $2.2 billion upfront with the potential for up to approximately $1.1 billion in additional regulatory and commercial milestone payments. Ollin was founded in 2023 with a mission to identify and accelerate the development of...

Ollin Biosciences Announces Presentations and Symposium at EURETINA 2026

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced an upcoming presentation of results from its previously completed head-to-head JADE proof-of-concept clinical trial evaluating OLN324 versus faricimab (Vabysmo®) in patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (wAMD) at the 26th European Society of Retina Specialists (EUR...

Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of OLN324 in DME and Wet AMD; Studies Commencing in Second Half of 2026

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced an oversubscribed $330 million Series B financing. The financing round was co-led by new investor TCGX and founding investor ARCH Venture Partners, with participation from a syndicate of leading healthcare-focused crossover investors, sovereign wealth funds and other institutional investors new to Ollin, including a16z Bio...
Back to Newsroom